

Get in the KNOW
on LA Startups & Tech
XMeet the Startup That Wants To Deliver Ketamine to Your Door
David Shultz
David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.
Ketamine is on the come up in the pharmaceutical world. Once confined to nightclubs and operating rooms, the drug is quickly gaining recognition as a valuable tool for treating mental health disorders including depression and anxiety.
Amid these rising tides, Wondermed has emerged, offering telehealth consultations and, potentially, the ability to deliver the drug right to your doorstep—all while building out a virtual platform and collecting data on how to use the molecule more effectively.
At the moment, the company provides a mail order service for courses of ketamine lozenges to those who’ve been prescribed the drug along with a telehealth software bridge between doctor and patient. Wondermed currently operates in five states — California, Texas, Florida, New York and Connecticut, though it plans to expand to another eight to 10 states in the next two weeks.
In the long run however, its plans are much bigger than being a link between doctors and patients.
“We generate more than 3,000 data points on every patient that comes into the funnel, and actually receives the medication,” says co-founder & Managing Director Jose Aycart.
His company is building out its online platform to collect and analyze patient data and provide mental health support services that may be useful, regardless of whether or not a patient is taking ketamine.
These data show in granular detail how ketamine therapies work. Does the route of administration matter? Does time of day matter? What types of patients are most likely to experience positive outcomes? It’s this data that represents the biggest business opportunity for Wondermed. The specifics of the monetization are still being worked out, but Aycart says it will never sell anonymized patient data to other companies.
Wondermed is in the midst of a seed funding round, targeting $7 million by the end of the month; It’s raised $5.6 million so far.
The company makes a bit of revenue by charging patients for consultations, but in the event that a patient doesn’t wind up using Wondermed’s platform, the consultation fee is refunded. For patients who are prescribed ketamine, the company charges only as much as the drugs cost them ($249 per month, which includes four doses), so neither Wondermed nor the physicians in its employ are incentivized to over-prescribe.
The drugs themselves are supplied by Tailor Made Compounding, a pharmacy in Nicholasville, Kentucky, and Wondermed is working on additional contracts in the pipeline with several other suppliers.
. Wondermed’s transformation comes as ketamine, which has typically been restricted to use as a general anesthetic, is quickly gaining recognition as a valuable tool for treating mental health disorders like depression and anxiety.
“What I’ve found interesting is how rapidly this field has emerged,” says Steven Grant, a drug and addiction researcher who spent 25 years at the National Institute on Drug Abuse and is now retired.

Ketamine is a simple organic molecule that first gained clinical popularity in the 1960s as an anesthetic. It produces a dissociative state in patients and dulls pain. Once in the bloodstream, the molecule travels to the brain where it binds to a protein called NMDA on the surface of neurons. NMDA has a variety of jobs, but it’s best-known for its role in learning, memory, and neuroplasticity—or the brain’s ability to form new pathways between neurons.
While the research into why ketamine is such an effective treatment for depression and anxiety is ongoing, the consensus so far is that the molecule’s power comes from this ability to rewrite or rewire the brain’s circuitry. If you’ve ever had an anxiety attack or a depressive episode, it can often feel like you’re stuck in a mental loop. Ketamine, it seems, offers a way to break that loop.
“It was this idea that you're increasing your neurological connections in the brain,” says Aycart. “You have the opportunity now to spark new forms of thought, new forms of emotion, or even new ideas.”
Unlike selective serotonin reuptake inhibitors (SSRIs) and other traditional drugs used to treat depression, ketamine’s effects are fast-acting—often appearing within minutes or hours of administration—and don’t require taking the drug daily.
“It really is revolutionary, and that’s why now more than ever, people are starting to get access to it, and companies like ourselves are really trying to bring it to people as an alternative form of medicine,” says Aycart.
Grant says the rise of ketamine clinics and telehealth services like Wondermed are likely a net positive because they increase patient access to drugs patients need, but he also has reservations about how the therapies are being applied.
Many of these psychoactive drugs—especially ketamine—are intended to be used in tandem with therapy, or at least under the supervision of a trained professional. Increasing the brain’s plasticity is a valuable tool for breaking out of depressive loops, but unless a professional is there to help the patient settle into a healthier mental pattern, the full benefits may be left on the table.
Wondermed offers a variety of supplementary support and strategies along with the drugs themselves, but taking advantage of these tools is left to the patient’s discretion. Grant would like to see a larger focus on extending and expanding that auxiliary support.
The company says it’s focused on building out the platform’s nonmedicinal mental health strategies—things like breathwork, meditation, music therapy—and adding them to an app. If they can get enough people on board, the eventual plan could be to sell health insights back to patients through a subscription model or something similar. They may even patent their own psychedelic molecules in the future. But all of this is likely quite a ways out.
“What we're trying to do is very new, and the landscape yet hasn't been built out,” says Aycart.
Clarification: This story has been updated to clarify Wondermed's monthly rate for ketamine lozenges.
From Your Site Articles
- Psychedelic Therapies Are Gaining Steam as Attitudes Change - dot ... ›
 - Ketamine for Depression Is Now Available by Injection - dot.LA ›
 - Ketamine Clinics Are Opening Across Los Angeles - dot.LA ›
 - Pasithea Opens a Chic Clinic in Beverly Hills to Administer Ketamine - dot.LA ›
 - New Pasithea Ketamine Clinic In Beverly Hills - dot.LA ›
 - Pasithea Opens a Ketamine Clinic In Beverly Hills - dot.LA ›
 
Related Articles Around the Web
David Shultz
David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.
LA Tech Week: Final Days • Coco’s bots, Anduril’s helmet AI, Impulse’s moon freight
08:05 AM | October 17, 2025
🔦 Spotlight
Happy Friday Los Angeles,
Founders are closing out Tech Week, robots are getting a new research brain, space logistics are taking shape, and defense tech just moved mission command into a helmet.
Anduril’s EagleEye: mission command, heads up
 
Anduril introduced EagleEye, a helmet mounted system that puts maps, comms, sensor fusion, and on device AI directly in a warfighter’s line of sight, integrated with the Lattice stack. The goal is simple: less time looking down at a tablet and more decisions made at the edge.
Impulse Space: a practical path to lunar deliveries
 
Impulse outlined a two piece ride to the Moon. Its Helios stage ferries an Impulse built lander to lunar orbit in about a week, the lander detaches, then descends to the surface without in-space refueling. The company says each mission could carry about three tons and that starting in 2028 it could run two missions per year for roughly six tons total, filling the gap between today’s small CLPS deliveries and future heavy landers.
Coco Robotics: new lab, new chief AI scientist
 
Coco named UCLA’s Bolei Zhou chief AI scientist and is launching a physical AI research lab to turn years of curbside driving data into faster, more autonomous sidewalk deliveries. Expect quicker iteration from data collection to local models on the bots.
LA Tech Week: last three days
We are down to the final few days of LA Tech Week 2025. If you are still slotting meetings or panels, use the rundowns to plan your route:
Scroll for the most recent LA venture deals, funds, and acquisitions.
🤝 Venture Deals
LA Companies
- Second Nature, an AI role-play training platform for sales and service teams, raised $22M Series B led by Sienna VC with participation from Bright Pixel, StageOne Ventures, Cardumen, Signals VC, and Zoom (also a customer). The company will use the funding to expand operations and advance its platform, which generates AI-driven practice scenarios and feedback for enterprise clients like Oracle, Zoom, Adobe, Teleperformance, and Check Point. - learn more
 
- Pelage Pharmaceuticals, a Los Angeles–based biotech developing regenerative treatments for hair loss, raised a $120M Series B co-led by ARCH Venture Partners and GV. Participants include Main Street Advisors, alongside Visionary Ventures and YK Bioventures; proceeds advance PP405, a topical small molecule that reactivates dormant hair-follicle stem cells, toward Phase 3 in 2026 following positive Phase 2a data. - learn more
 
- Launchpad, an AI-first robotics company for factory automation, raised an $11M Series A to speed product development and meet demand across the U.S., U.K., and Europe. The round was co-led by Lavrock Ventures and Squadra Ventures, with participation from Ericsson Ventures, Lockheed Martin Ventures, Cox Exponential, and the Scottish National Investment Bank; it follows $2.5M in grant funding from Scottish Enterprise. - learn more
 
- Mythical Games raised a Series D round, with a strategic investment from Eightco Holdings alongside ARK Invest and the World Foundation. The partnership focuses on human verification and digital identity in gaming, tapping Worldchain/Worldcoin’s Proof-of-Human infrastructure. The transaction is expected to close the week of October 20. - learn more
 
- Electric Entertainment, the L.A. studio behind “Leverage,” “The Librarians,” and “The Ark,” secured a $20M investment from Content Partners Capital. The funding follows CPC’s launch of an investment arm in April 2024 and is aimed at supporting Electric’s growth across production and distribution. - learn more
 
- Everyset raised $9M to launch Background Payroll, a SAG-AFTRA approved platform that automates timecards and payroll for background performers, including overtime, penalties, and premiums. The round was led by Crosslink Capital and Haven Ventures, and the company says studios such as Netflix, CBS, Apple TV, Sony, and Amazon already use its tools as it expands into fully integrated background payroll. - learn more
 
- TORL Biotherapeutics raised $96M in Series C funding to advance TORL-1-23, its Claudin-6 targeted antibody-drug conjugate, through a pivotal Phase 2 study in platinum-resistant ovarian cancer and into a confirmatory Phase 3 program. The company also reported that updated Phase 1 data for TORL-1-23 will be presented at ESMO 2025, bringing total funding since its 2019 founding to more than $450 million. - learn more
 
- The Plug, a plant-based liver health brand, raised $5M in a venture round of equity and debt to fuel marketing and retail expansion after rolling out its Pill Jar in June and entering all Total Wine & More locations nationwide in September. The company is keeping the round open for additional strategic investors and says it recently hit its first profitable month, is pursuing a partnership with a $500 million nutrition telehealth company, and is targeting a 40% boost to gross margins through a new operational milestone. - learn more
 
LA Venture Funds
- Clocktower Technology Ventures participated in MGT’s $21.6M Series B, an oversubscribed round led by Mubadala Capital with Tacora Capital and existing backers also joining. The AI-native commercial P&C neo-insurer for small businesses will use the capital to accelerate R&D, deepen vertical AI capabilities, and expand its E&S initiatives nationwide. - learn more
 
- M13 participated in Daylight’s $75M financing, which combines $15M in equity led by Framework Ventures with a $60M project facility led by Turtle Hill Capital. Daylight is building a decentralized energy network that turns homes into mini power plants via a subscription model and crypto-enabled incentives, aiming to lower costs and dispatch battery power back to the grid. - learn more
 
- Presight Capital co-led Peptilogics’ $78M Series B2, with Beyond Ventures participating, to fund a Phase 2/3 pivotal trial of zaloganan (PLG0206) for prosthetic joint infections. The raise brings Peptilogics’ total equity financing to about $120M and positions the company to begin the pivotal program in late 2025, pending approvals. - learn more
 
- Patron participated in Ego AI’s $6.7M seed round to help the YC-backed startup launch human-like AI characters for games via its new character.world engine. The round also included Y Combinator, Accel, and Boost VC, and the capital will support research on Ego’s proprietary model, which combines small language models with reinforcement learning, plus partnerships in Singapore to scale compute and development. - learn more
 
- Untapped Ventures participated in Woz’s $6M seed round, joining Cervin Ventures (lead), Y Combinator, Burst Capital, MGV, and the Lacob family. The funding will help Woz scale its platform that blends agentic AI with expert human oversight to deliver production-ready mobile apps for enterprises. - learn more
 
- Perseverance Capital participated in Kailera Therapeutics’ $600M Series B, which was led by Bain Capital Private Equity. The funding advances KAI-9531, an injectable dual GLP-1/GIP agonist, into global Phase 3 trials by year end and supports a broader pipeline of oral and injectable obesity therapies. - learn more
 
- March Capital participated in Lila Sciences’ $350M Series A, which lifts the company’s total funding to $550M. The capital will scale Lila’s AI Science Factories and commercialize its “scientific superintelligence” platform for partners across materials, energy, and biopharma. - learn more
 
- Mucker Capital participated in Pear Suite’s $7.6M Series A, which was co-led by Rock Health Capital and Nexxus Holdings. The L.A. based company equips community health workers with an AI-powered platform and provider network, and it will use the funding to expand product development, grow its network, and support new Medicaid and Medicare health plan contracts. Other investors include Enable Ventures, The SCAN Foundation, Acumen America, Impact Engine, and the California Health Care Foundation. - learn more
 
- Upfront Ventures participated in Renew’s $12M Series A, which was led by Haymaker Ventures with Goldcrest Capital and several Renew customers also investing. Renew’s AI-powered resident retention platform helps apartment operators automate renewals and prevent fraud, and the company says the new funding will scale the product and launch what it calls the industry’s first Resident Referral Network. - learn more
 
- Acre Venture Partners co-led Ascribe Bio’s oversubscribed $12M Series A with Corteva to scale its natural crop protection platform and launch Phytalix, a broad spectrum “biofungicide without compromise.” The funding advances Ascribe’s small molecule technology derived from the soil microbiome toward commercial rollout, with participation from Syngenta Group Ventures, Trailhead Capital, Silver Blue, Cultivation Capital, and others. - learn more
 
- Alexandria Venture Investments participated in Tr1X’s $50M financing, announced alongside FDA clearance of the IND for TRX319, an allogeneic CAR-Tr1 Treg cell therapy for progressive multiple sclerosis. The funding extends Tr1X’s runway into 2027 and supports a Phase 1/2a dose-escalation trial slated to start in early 2026, while the company continues its TRX103 studies in Crohn’s disease and other indications. - learn more
 
- LFX Venture Partners participated in FleetWorks’ $17M funding, which supports the launch and expansion of its “always-on” AI dispatcher for the U.S. trucking industry. The round was led by First Round Capital with participation from Y Combinator and Saga Ventures, and the company says the capital will go toward hiring, commercial rollout, and product development. FleetWorks’ platform automates freight matching between carriers and brokers to speed up bookings and reduce manual calls, emails, and texts. - learn more
 
- Clocktower Technology Ventures participated in Yendo’s $50M Series B. The fintech behind a vehicle-secured credit card will use the funding to expand its AI credit platform toward an inclusive digital bank that taps “trapped” consumer equity, aiming to unlock up to $4 trillion from assets like cars and homes for underserved borrowers. - learn more
 
- Alpha Edison participated in TransCrypts’ $15M seed round. The company builds a blockchain-based verified-credentials platform to fight AI-driven fraud and plans to expand beyond employment verification into health and education records. - learn more
 
- Alexandria Venture Investments participated in Nilo Therapeutics’ $101M Series A, which launched the company to develop medicines that modulate neural circuits to restore immune balance in disease. The round was led by The Column Group, DCVC Bio, and Lux Capital; Nilo also appointed Kim Seth, Ph.D., as CEO and plans to build out New York labs and advance preclinical programs. - learn more
 
- Chapter One participated in Glue’s $20M Series A. Glue builds an “agentic team chat” platform that embeds MCP-powered AI directly in workplace messaging, with 35 in-app integrations and support for thousands more via custom MCP servers. The funding will help expand product development and infrastructure as Glue pushes this model to more teams. - learn more
 
- StillMark participated in Meanwhile’s $82M raise, backing the Bermuda-regulated bitcoin life insurer as it expands bitcoin-denominated savings, retirement, and life insurance products for individuals and institutions. The round was co-led by Bain Capital Crypto and Haun Ventures with participation from Apollo, Northwestern Mutual Future Ventures, and Pantera Capital, and brings Meanwhile’s 2025 funding to $122 million after an earlier $40 million Series A. - learn more
 
- Blue Bear Capital co-led Energy Robotics’ $13.5M Series A with Climate Investment. The Darmstadt-based company provides AI software that lets robots and drones autonomously inspect critical infrastructure, and it will use the funding to scale deployments across energy, chemical, industrial, and utility sites. Customers already include majors like Shell, BP, BASF, Merck, and E.ON, and the company reports more than one million inspections completed to date. - learn more
 
- B Capital participated in EvenUp’s $150M Series E, which values the AI legal-tech company at over $2 billion. EvenUp builds AI tools for personal-injury law firms and plans to use the new capital to scale its platform and product suite; the round was led by Bessemer Venture Partners, with investors including REV (LexisNexis) and others. - learn more
 
- WndrCo participated in Zingage’s $12.5M seed round to build an AI care-delivery platform for home-based healthcare. Zingage is rolling out “Operator,” which automates scheduling, staffing, billing, and compliance for home care agencies, and “Perform,” which boosts caregiver retention, with the new capital supporting product expansion and go-to-market. The round was led by Bessemer Venture Partners with additional investors including TQ Ventures and South Park Commons. - learn more
 
- Alexandria Venture Investments participated in AeroRx Therapeutics’ $21M Series A, which was led by Avalon BioVentures with Correlation Ventures also investing. The funding advances AERO-007, a first-in-class nebulized LABA/LAMA for COPD, into late-stage clinical development aimed at patients who struggle with handheld inhalers. - learn more
 
- Alexandria Venture Investments participated in Affinia Therapeutics’ $40M Series C, alongside lead investor NEA and new investor Eli Lilly, to advance its AAV gene therapy pipeline. Proceeds will fund an IND submission in Q4 2025 and initial clinical work for AFTX-201 in BAG3 dilated cardiomyopathy, with a Phase 1/2 trial targeted for Q1 2026. - learn more
 
- Clocktower Ventures participated in Vycarb’s $5M seed round, which was led by Twynam with participation from MOL Switch, Hatch Blue, Idemitsu, and SGInnovate. The Brooklyn startup develops sensor-driven, water-based carbon capture and storage systems that convert CO₂ into stable bicarbonate, with the new funding aimed at scaling deployments at industrial sites. - learn more
 
LA Exits
- Empaxis Data Management was acquired by Communify, which is integrating Empaxis’ custodial and accounting data connections and operations expertise into its financial AI platform. The aim is to remove fragmented data so wealth and asset managers can deploy MIND AI apps like Client Stories and Portfolio Stories more quickly with cleaner, unified data. Communify also cites pre-integrations with over 175 market-data vendors to speed rollouts. - learn more
 
- TrueCar is being acquired by founder-led Fair Holdings (Scott Painter) in an all-cash deal at $2.55/share (~$227M), with Painter set to return as CEO. A 30-day go-shop runs through Nov. 13, 2025; largest holder Caledonia supports the acquisition, which is expected to close Q4 2025 or early 2026 pending approvals. - learn more
 
- Kate Somerville Skincare was acquired by Rare Beauty Brands, as Unilever moves to divest the prestige label it has owned for a decade. The deal includes the skincare and body-care lines as well as the brand’s Melrose Place clinic in Los Angeles; terms weren’t disclosed and closing is expected in Q4 2025 pending approvals. - learn more
 
- 3GC Group was acquired by Pandoblox, combining 3GC’s enterprise IT operations and cybersecurity services with Pandoblox’s Themis AI data platform to form a unified, AI-ready data and IT operations offering for mid-market companies. The deal aims to solve fragmented data and IT workflows so growing businesses can get enterprise-grade intelligence, security, and support through a single partner. - learn more
 
- The Free Press was acquired by Paramount, and co-founder Bari Weiss will become editor in chief of CBS News as part of the deal. Paramount says the move pairs CBS News’ scale with The Free Press’ voice, with Weiss reporting to CEO David Ellison and working to “modernize” the brand. - learn more
 
Read moreShow less
Cap Tables to Costumes: Whatnot’s Mega Round and Your LA Weekend Plan 🎃
10:39 AM | October 31, 2025
🔦 Spotlight
Happy Friday Los Angeles!
Live shopping’s LA moment
Whatnot, the LA born marketplace for live auctions, raised $225 million at an $11.5 billion valuation. The round was co led by DST Global and CapitalG, with Sequoia, Alkeon, a16z, Greycroft, BOND, and others participating. The company says the money goes to international expansion, trust and safety, and seller tools - fuel for a category that has moved from “Is this a fad?” to “How big does this get in the West?”
Why it matters
If that valuation sounds sudden, you’re not imagining it. Whatnot’s last raise in January valued the company around $5 billion. Less than 10 months later, the number has more than doubled, tracking a year of surging GMV and a social commerce flywheel spinning across TikTok Shop, YouTube, and Amazon. For LA, it’s a marquee bet on the creator commerce stack we do best: community, content, and culture that converts
The bigger picture
The implications go well beyond trading cards. Live, personality led storefronts are evolving from hobby to underwritable small business. If Whatnot uses this cash to keep fraud low and throughput high, we could see an LA export take root globally, not just as an app category but as a job category. That is a storyline to watch into Q4 and beyond.
From cap tables to costumes: Halloween in LA 🎃
You’ve earned some offline fun. Heading into Halloween weekend (Oct. 31–Nov. 2), LAist’s guide has a little of everything: neighborhood Día de los Muertos celebrations (from the Canoga Park family festival to an ofrenda for pets at Annenberg PetSpace in Playa Vista), the Frogtown Arts weekend along the LA River, plus plenty of screenings and concerts across town. Bookmark the list, pick your neighborhood, and maybe swap “add to cart” for “add to calendar.”
Send tips, sightings, and spooky term sheets our way. Venture deals for LA companies, funds, and acquisitions are below.
🤝 Venture Deals
LA Companies
- Bryan Johnson’s longevity startup Blueprint raised $60M from a celebrity heavy group of backers including Kim Kardashian, Naval Ravikant, Alex Hormozi, Ari Emanuel, and the Winklevoss twins to turn Johnson’s personal Blueprint regimen into a broader consumer platform. The company says the funding will help package diagnostics, biomarker tracking, prescriptions, nutrition, and other longevity services into an accessible offering. The round underscores mainstream interest in data driven wellness despite past questions about Blueprint’s trajectory. - learn more
 
- Rarity PBC raised $4.6M in seed financing to advance a one-time, autologous blood-stem-cell gene therapy for ADA-SCID (“bubble baby” disease) that it has licensed from UCLA researcher Dr. Donald Kohn. The round, led by biotech investor Steve Oliveira (Nemean Asset Management), will support manufacturing and steps toward commercial readiness. - learn more
 
- Fruitist raised $150M led by a vehicle managed by J.P. Morgan Asset Management, with participation from Aliment Capital and Ray Dalio’s family office. The LA-based superfruit brand says the funding will fuel crop expansion, cold storage, and automation as it scales distribution to 12,500+ stores and targets continued growth following roughly $400M in trailing sales. - learn more
 
- Homecourt, the Los Angeles based luxury home and personal fragrance brand founded by Courteney Cox, raised an $8M Series A led by CULT Capital. The company says the funding will fuel brand marketing, team hires, and infrastructure as it expands beyond DTC into 300+ retail doors including Nordstrom, Bluemercury, and Revolve. Homecourt has broadened from home care into body and laundry collections since launching in 2022. - learn more
 
LA Venture Funds
- Aliavia Ventures participated in Human Health’s $8.5M raise, joining LocalGlobe, Airtree, Skip Capital and Scale Investors to back the precision health platform from former Canva product leaders Georgia Vidler and Kate Lambridis. The funding will support international expansion, deepen product intelligence in areas like women’s health, respiratory and pain, and scale Human Evidence for patient driven research; Human Health reports more than 200,000 users and 20 million logged health actions to date. - learn more
 
- Riot Ventures participated in EnduroSat’s $104M funding round, alongside Google Ventures, Lux Capital, the European Innovation Council Fund, and Shrug Capital. The Sofia based satellite manufacturer says the capital will scale production of its ESPA class (200 to 500 kg) modular satellite buses, targeting capacity of up to two satellites per day at a new 188,340 square foot Space Center so constellation customers can get to orbit faster. The raise is EnduroSat’s second this year and follows a €43 million round in May. - learn more
 
- Rocana Venture Partners participated in Recess’s $30M Series B, which was led by CAVU Consumer Partners and included Midnight Ventures, Torch Capital, Doehler Ventures, KAS Venture Partners, Vanquish, and Craig Kallman. The relaxation-beverage company will use the capital to grow its team, expand retail distribution, and ramp marketing, and it also named former Nutrabolt executive Kyle Thomas as President and Co-CEO to help scale the brand. Recess says it now sells in more than 15,000 U.S. stores, positioning it to capitalize on demand for functional relaxation and alcohol-alternative drinks. - learn more
 
- Terasaki Institute participated in iOrganBio’s $2M launch financing, joining First Star Ventures (lead), IndieBio, Cape Fear BioCapital, 2ndF, and Alix Ventures. The Chapel Hill based startup unveiled CellForge, an AI powered cell-manufacturing platform that pairs predictive models with high throughput control to engineer reproducible human cells and organoids for drug discovery and cell therapies. The funds support product development and early deployments. - learn more
 
- Fox Sports made a strategic investment in Shadow Lion, the creative agency and IP studio co-founded by Tom Brady, forming a partnership to develop talent-led originals, digital content, long-form projects, and marquee live events. The deal includes a new Los Angeles hub for Shadow Lion on the Fox lot, with early tentpoles including a University of Michigan football docuseries from executive producers Brady and Jim Harbaugh and collaboration on the Fanatics Flag Football Classic. - learn more
 
- EB Medical Research Foundation participated in Eliksa Therapeutics’ funding to advance ELK-003, a biological eye drop for ocular complications in epidermolysis bullosa. The round, led by DEBRA Research with support from Cure EB, the Abe Fund, and EB Research Partnership, backs an ongoing pilot study with 18 patients enrolled and no drug-related side effects reported among the first eight who completed treatment. - learn more
 
- Patron and HartBeat Ventures participated in Sweatpals’ $12M seed round alongside a16z speedrun, backing the community fitness platform as it expands its “daylife” model of IRL wellness events. The funding will support product and market expansion for hosts and gyms using Sweatpals for discovery, ticketing, memberships, and marketing. Business Insider reports the startup now reaches over 1 million monthly users and is growing into new U.S. cities. - learn more
 
- UP.Partners participated in Lula Commerce’s $8M Series A, led by SEMCAP AI with Rich Products Ventures, GO PA Fund, NZVC, Green Circle Foodtech Ventures, and Outlander VC also joining. The Philadelphia company, active with more than 2,000 retailers, offers an AI powered digital commerce suite for convenience stores covering order ahead, pickup, delivery, and back office tools, and says the round brings total funding to over $16M to meet rising demand. - learn more
 
- Navitas Capital led WorkHero’s $5M seed to scale its AI powered back office platform for small HVAC contractors, with Workshop Ventures, York IE, and strategic angels also participating. WorkHero combines agentic AI with human account managers to handle invoicing, permits, rebates, warranty registrations, and pricebooks so owners spend less time on admin. The funding will expand engineering and product and add new services such as call answering and bookkeeping. - learn more
 
LA Exits
- DMI was acquired by Stingray, adding about 8,500 U.S. retail locations to Stingray’s in-store audio advertising network and bringing its total footprint to roughly 33,500 sites. The deal cements Stingray’s leadership in pharmacy retail audio across the two largest chains and brings DMI’s creative services, including cinema advertising and brand marketing, under its umbrella, with CEO Tena Clark staying on to help integrate and expand the offering. - learn more
 
Read moreShow less
RELATEDTRENDING
LA TECH JOBS


